CoChat
Cited by 206

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites

Quinten, Chantal, Martinelli, Francesca, Coens, Corneel, Sprangers, Mirjam A. G., Ringash, Jolie, Gotay, Carolyn, Bjordal, Kristin, Greimel, Eva, Reeve, Bryce B., Maringwa, John, Ediebah, Divine E., Zikos, Efstathios, King, Madeleine T., Osoba, David, Taphoorn, Martin J., Flechtner, Henning, Schmucker‐Von Koch, Joseph, Weis, Joachim, Bottomley, Andrew, on behalf of Patient Reported Outcomes and Behavioral Evidence (PROBE) and the European Organization for Research and Treatment of Cancer (EORTC) Clinical Groups · 2014 · Cancer

Abstract

BACKGROUND: The objective of this study was to examine the prognostic value of baseline health‐related quality of life (HRQOL) for survival with regard to different cancer sites using 1 standardized and validated patient self‐assessment tool. METHODS: In total, 11 different cancer sites pooled from 30 European Organization for Research and Treatment of Cancer (EORTC) randomized controlled trials were selected for this study. For each cancer site, univariate and multivariate Cox proportional hazards modeling was used to assess the prognostic value (P < .05) of 15 HRQOL parameters using the EORTC Core Quality of Life Questionnaire (QLQ‐C30). Models were adjusted for age, sex, and World Health Organization performance status and were stratified by distant metastasis. RESULTS: In total, 7417 patients completed the EORTC QLQ‐C30 before randomization. In brain cancer, cognitive functioning was predictive for survival; in breast cancer, physical functioning, emotional functioning, global health status, and nausea and vomiting were predictive for survival; in colorectal cancer, physical functioning, nausea and vomiting, pain, and appetite loss were predictive for survival; in esophageal cancer, physical functioning and social functioning were predictive for survival; in head and neck cancer, emotional functioning, nausea and vomiting, and dyspnea were predictive for survival; in lung cancer, physical functioning and pain were predictive for survival; in melanoma, physical functioning was predictive for survival; in ovarian cancer, nausea and vomiting were predictive for survival; in pancreatic cancer, global health status was predictive for survival; in prostate cancer, role functioning and appetite loss were predictive for survival; and, in testis cancer, role functioning was predictive for survival. CONCLUSIONS: The current results demonstrated that, for each cancer site, at least 1 HRQOL domain provided prognostic information that was additive over and above clinical and sociodemographic variables. Cancer 2014;120:302–311. © 2013 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.28382

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

Metadata

Authors
Quinten, C., Martinelli, F., Coens, C., Sprangers, M. A. G., Ringash, J., Gotay, C., Bjordal, K., Greimel, E., Reeve, B. B., Maringwa, J., Ediebah, D. E., Zikos, E., King, M. T., Osoba, D., Taphoorn, M. J., Flechtner, H., Schmucker‐Von Koch, J., Weis, J., Bottomley, A., & on behalf of Patient Reported Outcomes and Behavioral Evidence (PROBE) and the European Organization for Research and Treatment of Cancer (EORTC) Clinical Groups
Venue
Cancer
Publisher
Wiley
Published
2013-10-11
Volume
120
Issue
2
Pages
302-311
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1940624845
Cited by
206
References
3
FWCI
6.64
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.